Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
NCT00488605 · University of New Mexico · PHASE3 · withdrawn · last registry update 2023-08-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This is a duplicate record and the sponsor has registered the study.” | – | Registry record, University of New Mexico |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab Tirumotecan + Pemetrexed (NCT06459180)
- 2024-05-06Phase 3 first posted: Children's Oncology Group, Carboplatin + Cyclophosphamide (NCT06401330)
- 2024-04-24Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06382142)
- 2024-04-18Results posted on the registry: Adrienne G. Waks, Vinorelbine + Trastuzumab (NCT03414658)
- 2024-04-10Phase 3 first posted: Celgene, Golcadomide + Placebo (NCT06356129)
- 2024-04-03Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06343948)
- 2024-02-28Phase 3 first posted: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., SKB264 + Paclitaxel (NCT06279364)
- 2024-02-28Phase 3 first posted: The Lymphoma Academic Research Organisation, Mosunetuzumab + Lenalidomide (NCT06284122)
- 2024-02-16Phase 3 first posted: Intensity Therapeutics, Inc., INT230-6 + Eribulin (NCT06263231)
- 2024-01-23Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Dexrazoxane + Rituximab (NCT06220032)
- 2024-01-05Phase 3 first posted: Genmab, Epcoritamab + Prednisone (NCT06191744)
- 2024-01-03Phase 3 first posted: National Research Center for Hematology, Russia, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06188676)
- 2023-12-15Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06172296)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091865)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091254)
- 2023-10-10Phase 3 first posted: Acrotech Biopharma Inc., Belinostat Injection + Pralatrexate Injection (NCT06072131)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
- 2023-09-21Phase 3 first posted: Hoffmann-La Roche, Glofitamab + Polatuzumab vedotin (NCT06047080)
- 2023-09-13Results posted on the registry: Astellas Pharma China, Inc., Enfortumab vedotin (NCT04995419)
- 2023-06-15Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan (DS-8201a) + Capecitabine (NCT03734029)
- 2023-05-31Results posted on the registry: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT02166463)
- 2023-04-20Phase 3 first posted: Universität des Saarlandes, R-miniCHOP + Acalabrutinib + R-miniCHOP (NCT05820841)
- 2023-04-14Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel (NCT05814354)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2023-01-25Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Dasatinib (NCT02143414)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision